|
Showcase Your Research at ALS Nexus |
|
We’re inviting all researchers to share their latest results at our inaugural ALS Nexus conference in Dallas, Texas from July 14 to 17, 2024. The poster session serves as a platform to disseminate novel findings and exchange innovative ideas aimed at accelerating the discovery of new treatments and cures for ALS, optimizing patient care, and mitigating the impact of ALS-related harms. The deadline to submit an abstract is May 8, 12:00 p.m. ET. |
Amylyx Voluntarily Removes Relyvrio from the Market |
|
Based on topline results from the phase 3 PHOENIX trial, Relyvrio (AMX0035) is no longer available to new patients. People living with ALS who were receiving this therapy before April 4, 2024, have the option to continue taking it after consulting with their health care team. |
The ALS Association Partners with the Association
|
|
Two grants were recently awarded through the associations’ Digital Assessment Tools for FTD and ALS funding opportunity. These awards will help evaluate remote smartphone assessments of cognition, behavior, and motor function across the spectrum of FTD and ALS and identify the digital measures best suited to monitoring disease progression. |
Tauroursodeoxycholic Acid (TUDCA) Demonstrates
|
|
Topline results from the European study showed that 18 months of TUDCA treatment did not slow ALS progression. There also were no statistically significant differences between TUDCA and placebo related to survival or changes in biomarkers such as neurofilament light protein. |
|
|
|
ALS Focus: Clinical Trials and Treatment Needs Survey |
|
We want to know what should matter the most when new ALS drug treatments and clinical trial designs are being developed. People living with ALS and current or past caregivers can share their perspectives until May 31 to help researchers, drug developers, and policymakers better understand the needs and desires of the ALS community. No experience with clinical trials or drug treatments is necessary to participate.
CLICK HERE to learn more or take part in the survey. |
|
|
Association Leadership Takes Action on the Hill Subscribe today to follow our weekly blog and stay up to date with what’s happening in the ALS community. Visit our website HERE. |
|
Clinical Trials |
|
Clinical research is the only way that promising laboratory science can be translated into treatments and cures for ALS and other neurological diseases. People with ALS, along with family members and caregivers, are essential partners in this research. For the most accurate and up-to-date information on both federally and privately funded clinical studies focusing on ALS and other similar motor neuron diseases, visit our website. |
The National ALS Registry |
|
The National ALS Registry may be the single largest ALS research project ever created and is designed to identify ALS cases from throughout the entire United States. Every person living with ALS in the U.S. can take part, and there is no fee to participate. |
Webinars |
|
The ALS Association partners with the Northeast ALS Consortium (NEALS) to provide educational webinars for people with ALS, caregivers, and the broader ALS community. Topics include updates on clinical trials, best practices for clinical care, and current research efforts in ALS causes and treatments. |
|
For more details about current ALS research, our programs and awards, and the projects we fund, visit als.org/research. Stay up to date with the latest news in ALS care by signing up for our quarterly e-newsletter, Care Matters. We welcome all feedback, comments and questions you may have on anything about the information provided, suggestions of topics you would like to see in future newsletters or thoughts to help us improve. Please email us at communications@als.org. Research Matters will arrive in your inbox on the last Thursday of each month. To unsubscribe from future issues, please update your email preferences. |